^
Association details:
| Biomarker: | FLT3 D835 |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Rydapt (midostaurin) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)
Excerpt:
...Documented absence of an ITD and TKD activating mutation at codons D835 and I836 in the FLT3 gene, as determined by analysis in a Novartis designated laboratory using a validated clinical trial assay with clinical cutoff of 0.05 mutant to wild type signal ratio 4....
Trial ID:
Source:
Title:
PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)
Excerpt:
...Patients with a relevant FLT3-ITD mutation or D835Y point mutation 3....
Trial ID:
Less C2 evidence
Source:
Title:
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
Published date:
10/08/2020
Excerpt:
A total of 239 patients with FLT3-ITD- and/or FLT3-D835-mutated AML who received FLT3i-based treatments (including single-agent or combination FLT3i therapies) were identified...Of 10 patients harboring D835 TKD mutations, 7 achieved CRc (70%): 4 received sorafenib (3 achieved CRc), 3 quizartinib (2 achieved CRc), and 3 midostaurin (2 achieved CRc) as induction FLT3i.
DOI:
10.1186/s13045-020-00964-5
